Uteron Pharma, a Belgian spin-out of Liège University, is facing the prospect of having to fire up to 30 employees. This would cut the company’s total staff in half.
The company had only been acquired by Actavis (then Watson Pharmaceuticals) in January 2013 for an upfront cash payment of $150m and a potential further $155m in milestone payments. Watson has since completed the change of its company brand to Actavis, following its acquisition of the eponymous group for €4.25bn ($7bn).
…